Bet­ting ear­ly on an AI niche, RA Cap­i­tal seeds a young founder's quest to un­lock 'Holy Grail' tar­gets

Ar­ti­fi­cial in­tel­li­gence, with its grandiose claims and sweep­ing promis­es to rev­o­lu­tion­ize drug dis­cov­ery, may seem om­nipresent in bio­phar­ma now. But Vir­ginia Burg­er and RA Cap­i­tal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER